Appointments

Pantherix Names New Research Director

Published in TB and Outbreaks Week, November 13th, 2001

PanTherix Ltd., an emerging drug discovery company focused on the identification of novel anti-infectives, has appointed Christopher J. Latham, PhD, as research director. Dr. Latham brings extensive experience in the areas of drug resistance and drug design.

Dr. Latham comes to PanTherix from Sanofi-Synthelabo, where he was head of cardiovascular chemistry from 1996. At Sanofi-Synthelabo he had responsibility for development of the company's overall cardiovascular drug development strategy, managed a number of significant research programs and established new approaches to lead generation and drug design. Dr. Latham also facilitated important corporate collaborations...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2001-11-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry